Prognostic gene expression and microRNA profiling signatures and genetic alterations in primary testicular diffuse large B-cell lymphoma

Lymphoma

Ibrutinib added to standard conditioning and as maintenance therapy following autologous hematopoietic stem cell transplantation for relapsed or refractory activated-B-cell type Diffuse Large B-cell lymphoma: primary analysis of the US intergroup double-blind randomized phase III study Alliance A051301/BMT-CTN 1201

Leuk Lymphoma

Andreadis C, Bobek O, Hsi ED, Fenske TS, Stiff PJ, Hill BT, Geyer SM, Horwitz M, Khimani F, Little RF, Dinner SN, Friedberg JW, Kahl BS, Perales MA, Devine SM, Leonard JP, Bartlett NL

doi: 10.1080/10428194.2025.2525982

Lymphoma

Allogeneic stem cell transplantation against aggressive lymphomas: graft-versus-lymphoma effects in peripheral T-cell lymphoma and diffuse large B-cell lymphoma after myeloablative conditioning

Leuk Lymphoma

Shumilov E, Levien L, Mazzeo P, Jung W, Leha A, Koch R, Hasenkamp J, Wulf G

doi: 10.1080/10428194.2024.2438805

Lymphoma

Therapeutic approach to patients with early stage diffuse large B cell lymphoma: retrospective, multicenter, real-life study of the 'RTL' (regional Tuscan lymphoma network)

Leuk Lymphoma

Cencini E, Palazzo M, Dardanis D, Lucco Navei G, Mannelli L, Zoi V, Mecacci B, Sordi B, Cervetti G, Rosati S, Nassi L, Bocchia M, Fabbri A

doi: 10.1080/10428194.2025.2456094

Lymphoma

Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B cell Lymphoma

Clin Cancer Res

Jhaveri K, Thapa R, Ercan D, Saha A, Noble J, Singh P, Fahrmann J, Saini N, Wu R, Dennison JB, Hanash S, Jenq RR, Modi K, Figura N, Chavez J, Shah B, Nishihori T, Lazaryan A, Khimani F, Bachmeier C, Gage K, Mishra A, Perna F, Davila ML, Spiegel J, Rejeski K, Subklewe M, Locke FL, Freeman C, Parker N, Jain MD

doi: 10.1158/1078-0432.CCR-24-3782

Lymphoma

CNS Relapse in High-Grade B-cell Lymphoma with MYC and BCL2 Rearrangements and Dark-Zone Signature-Expressing DLBCL

Blood

Alduaij W, Jiang A, Villa D, Collinge BJ, Ben-Neriah S, Boyle M, Meissner B, Hilton LK, Farinha P, Slack GW, Craig JW, Gerrie AS, Freeman CL, Mungall AJ, Steidl C, Sehn LH, Scott DW, Savage KJ

doi: 10.1182/blood.2024025725

Lymphoma

A comparative analysis of transformed indolent lymphomas and de novo diffuse large B-cell lymphoma: a population-based cohort study

Blood Cancer J

Vaughn JL, Ramdhanny A, Munir M, Rimmalapudi S, Epperla N

doi: 10.1038/s41408-024-01194-5

Lymphoma

Outcomes with loncastuximab tesirine following CAR T-cell therapy in patients with relapsed or refractory diffuse large B-cell lymphoma

Blood Cancer J

Epperla N, Lucero M, Bailey T, Mirams L, Cheung J, Amet M, Milligan G, Chen L

doi: 10.1038/s41408-024-01195-4

Lymphoma

Loncastuximab in high-risk and heavily pretreated relapsed / refractory diffuse large B-cell lymphoma: a real-world analysis from 21 US centers

Haematologica

Zelikson V, Gurumurthi A, Sawalha Y, Annunzio K, Saha A, Dong N, Qualls D, Amoozgar B, Kahl B, Baird J, Challa P, Huntington SF, Santos J, Bair S, Narkhede M, Li S, Frosch Z, Ho C, Smith SD, Winter A, Landsburg D, Furqan F, Hamadani M, Baird K, Romancik J, Alharthy H, Law J, Bojanini L, Advani R, Hu B, Johnson PC, Grover NS, Merril M, Crombie JL, Shafagati N, Sterling C, Nastoupil LJ, Epperla N, Ayers EC

doi: 10.3324/haematol.2024.285977

Lymphoma

Distinct subtypes of post-transplant lymphoproliferative disorders: CHIP-like mutations in early lesions and substantial mutational differences between EBV-positive and EBV-negative diffuse large B-cell lymphomas

Br J Haematol

Ivanova VS, Menter T, Cui N, Leary P, Zinner C, Halter JP, Stenner F, Dirnhofer S, Müller A, Tzankov A

doi: 10.1111/bjh.19952

Related content

Allogeneic stem cell transplantation against aggressive lymphomas: graft-versus-lymphoma effects in peripheral T-cell lymphoma and diffuse large B-cell lymphoma after myeloablative conditioning

Therapeutic approach to patients with early stage diffuse large B cell lymphoma: retrospective, multicenter, real-life study of the 'RTL' (regional Tuscan lymphoma network)

Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B cell Lymphoma

CNS Relapse in High-Grade B-cell Lymphoma with MYC and BCL2 Rearrangements and Dark-Zone Signature-Expressing DLBCL

A comparative analysis of transformed indolent lymphomas and de novo diffuse large B-cell lymphoma: a population-based cohort study

Outcomes with loncastuximab tesirine following CAR T-cell therapy in patients with relapsed or refractory diffuse large B-cell lymphoma

Loncastuximab in high-risk and heavily pretreated relapsed / refractory diffuse large B-cell lymphoma: a real-world analysis from 21 US centers

Distinct subtypes of post-transplant lymphoproliferative disorders: CHIP-like mutations in early lesions and substantial mutational differences between EBV-positive and EBV-negative diffuse large B-cell lymphomas